Date: 2015-07-08
Type of information: Collaboration agreement
Compound: high-throughput sequencing techniques
Company: Integragen (France) AP - HP (Assistance Publique - Hôpitaux de Paris) (France) Georges Pompidou European Hospital (HEGP) (France)
Therapeutic area: Cancer - Oncology
Type agreement: collaboration
Action mechanism:
Disease:
Details: * On July 8, 2015, IntegraGen, a French leading player in genome analysis, development and commercialization of molecular diagnostic tests, and the Georges Pompidou European Hospital (HEGP) announced the signing of an agreement to develop the use of high-throughput sequencing techniques to improve the care of patients. As part of this agreement, clinicians and biologists at HEGP will utilize sequencing capabilities in combination with bioinformatic analysis techniques developed jointly with IntegraGen to allow for the rapid interpretation of genomic data. This will enable the ability to refer patients, particular those with cancerous tumors, to targeted therapies.
Financial terms:
Latest news:
